Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Science"
DOI: 10.1111/cas.15736
Abstract: The safety of osimertinib is limited in patients with severe or moderate renal impairment, or low body weight. This study aimed to investigate the safety, pharmacokinetics (PK) and recommended dose (RD) of osimertinib in patients… read more here.
Keywords: body weight; low body; function low; renal function ... See more keywords